PhorMed
Unlocking Biotech Potential with Cellular Restoration
Overview
Raised: $0
Total Commitments ($USD)
Wefunder
10/26/2023
07/30/2024
$500
Equity - Common
Series A
RegCF
$1.00
$52,523,767
Rolling Commitments ($USD)
Active
05/01/2024
89
0%
0%
$0
2019
Healthcare & Pharmaceuticals
Biotech
B2B2C
Medium
High
Summary Profit and Loss Statement
| FY 2023 | FY 2022 | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-750,289 |
$-1,477,413 |
Summary Balance Sheet
| FY 2023 | FY 2022 | |
|---|---|---|
|
Cash |
$303 |
$171,333 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$646,384 |
$746,059 |
|
Short-Term Debt |
$1,392,000 |
$714,494 |
|
Long-Term Debt |
$8,493 |
$0 |
|
Total Liabilities |
$1,400,493 |
$714,494 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| PhorMed | 07/29/2024 | Wefunder | $52,523,767 | $0 | Equity - Common | Active | RegCF |
| PhorMed | 08/16/2022 | StartEngine | $51,647,023 | $243,864 | Equity - Common | Funded | RegCF |
| PhorMed | 03/24/2022 | StartEngine | $39,000,000 | $2,450,528 | Equity - Common | Funded | RegCF |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
